First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder

Annals of Hepatology

Volumn 12, Issue 1, 2013, Pages 156-160

  Nahdi, Nawal Al ^a,b   Ford, Jo Ann ^b   Greanya, Erica D ^a   Harrigan, Jo Ann ^c   Tse, Irene ^c   Steinbrecher, Urs P ^a,b   Erb, Siegfried R ^a,b   Yoshida, Eric M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Vancouver General Hospital ^*

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Boceprevir; Fibrosing cholestatic hepatitis; Hepatitis C; Liver transplant recipient

Indexed keywords

BILIRUBIN; BOCEPREVIR; CORTICOSTEROID; CREATININE; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; TACROLIMUS; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; ALPHA INTERFERON; ANTIVIRUS AGENT; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE; PEGINTERFERON ALPHA2B; PROLINE; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD TRANSFUSION; CADAVER DONOR; CASE REPORT; CHOLESTATIC HEPATITIS; COMPASSIONATE USE; DECOMPENSATED LIVER CIRRHOSIS; DETERIORATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ERYTHROCYTE CONCENTRATE; FEMALE; FIBROSING CHOLESTATIC HEPATITIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; NEUTROPENIA; PERITONEUM VEIN SHUNT; PORTAL HYPERTENSION; SIDE EFFECT; VIRUS LOAD; BLOOD; DRUG COMBINATION; DRUG EFFECT; HEPATITIS C VIRUS; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TACROLIMUS; TREATMENT OUTCOME; VIRAL LOAD;

MLCS; MLOWN;

EID: 84878746682     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31400-0     Document Type: Article

References (21)

1. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, Fiel I, et al. Severe recurrent cholestatic hepatitis C following orthoptic liver transplantation. Hepatology 1996; 23: 971-6.
2. Furuta K, Takahashi T, Aso K, Hoshino H, Sato K, Kakita A. Fibrosing cholestatic hepatitis in a live transplant recipient with hepatitis C virus infection: a case report. Transplant Proc 2003; 35: 389-91.
3. Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007; 13: 219.
4. Fang JW, Wright TL, Lau JY. Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet 1993; 342: 1175.
5. Saleh F, Ko HH, Davis JE, Apiratpracha W, Powell JJ, Erb SR, Yoshida EM. Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis. Ann Hepatol 2007; 6: 186-9.
6. Wasmuth JC, Fischer HP, Sauerbruch T, Dumoulin FL. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphmamide/rituximab for low grade non-Hodgkin's lymphoma. Eur J Med Res 2008; 13: 483-6.
7. Lisa RD, James MC. Early histologic changes in Fibrosing cholestatic hepatits C. Liver Transpl 2007; 13: 219-26.
8. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, Williams R. Hepatic histological finding after transplantation for chronic hepatitis B infection, including a unique pattern of Fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-7.
9. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, Fiel I, et al. Severe recurrent cholestatic hepatitis C following orthoptic liver transplantation. Hepatology 1996; 23: 971-6.
10. Pessoa MG, Bzowej N, Berenguer M, Phung Y, Kim M, Ferrell L, Hassoba H, et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999; 30: 1513-20.
11. Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, Moya A, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-10.
12. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-anaylsis. Liver Transpl 2007; 13: 21-9.
13. Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, et al. Successful treatment of Fibrosing cholestatic hepatitis after liver transplantation. Transplant Proc 2011; 43: 905-8.
14. Bolkhir A, Brunt EM, Solomon HS, Hayashi PH. Sustained resolution of Fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy. Liver Transpl 2007; 13: 309-11.
15. Incivek (Telaprevir) (package insert). Cambridge, Mass: Vertex Pharmaceuticals; 2011.
16. Victrelis (boceprevir) (package insert). Whitehouse Station, NJ: Merck&Co; 2011.
17. Bacon BR, Gordon SC, Lawitz E, Marcellin P, et al. Boceprevir for previously treated chronic HCV genotype1 infection. N Engl J Med 2011; 364: 1207-17.
18. Vierling J, Flamm S, Gordon S, Lawitz E, Bronowicki JP, Davis M, Yoshida E, et al. Efficacy of Boceprevir in Prior Null Responders to Peginterferon/Ribavrin: the PROVIDE Study. Hepatology 2011; 54(Suppl.): 796-77A (Abstract).
19. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 608-18.
20. Wilby KJ, Greanya E, Ford JE, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11: 197-85.
21. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic hepatitis C genotype 1 infection. N Engl J Med 2011; 364: 1195-20.